An update on the safety of long-term vedolizumab use in inflammatory bowel disease-Reference-Cited by-同舟云学术

An update on the safety of long-term vedolizumab use in inflammatory bowel disease

Published:2023-08-23 Issue:9 Volume:22 Page:767-776
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Honap Sailish¹²,Netter Patrick³,Danese Silvio⁴,Peyrin-Biroulet Laurent⁵⁶⁷⁸

Affiliation:

1. Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, London, UK

2. School of Immunology and Microbial Sciences, King’s College London, London, UK

3. Ingénierie Moléculaire et Ingénierie Articulaire (IMoPA), UMR-7365 CNRS, Faculté de Médecine, University of Lorraine and University Hospital of Nancy, Nancy, France

4. Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy

5. Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France

6. INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France

7. Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD center, Neuilly sur Seine, France

8. Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2247976

Reference84 articles.

1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

3. Unravelling the pathogenesis of inflammatory bowel disease

4. Integrins

5. Targeting integrin pathways: mechanisms and advances in therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. May ChatGPT be a tool producing medical information for common inflammatory bowel disease patients’ questions? An evidence-controlled analysis;World Journal of Gastroenterology;2024-01-07

2. Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis;Journal of Clinical Medicine;2023-10-23